FDA approval for DefenCath (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections – CorMedix
CorMedix Inc. announced that the FDA has approved DefenCath (taurolidine and heparin) catheter lock solution (CLS) to reduce the incidence of catheter-related bloodstream infections (CRBSIs) for the limited… read more.
